Researchers described an automated platform that optimizes enzyme production using cell-free protein synthesis combined with AI-driven design. The approach targets faster iteration in biomanufacturing development, where enzyme yield and performance depend on multiple controllable variables across expression and formulation. The system is built to reduce trial-and-error cycles by connecting cell-free synthesis workflows to computational design methods that propose modifications and evaluate outcomes. By enabling iterative improvement within shorter turnaround windows, the platform is positioned to support enzyme creation for pharmaceutical manufacturing and other industrial bioprocesses. While specific enzymes and performance metrics were not detailed in the provided excerpt, the core development is a workflow that integrates automation, cell-free expression, and machine learning to converge on better production conditions.